Trials / Conditions / Hematological Diseases

Hematological Diseases

26 registered clinical trials studyying Hematological Diseases — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation NCT06281496	Rigshospitalet, Denmark	N/A
Completed	Late Effects and HRQoL in Survivors of Allo-HSCT - a Cross Sectional Study NCT06277479	Rigshospitalet, Denmark	—
Unknown	Assessment of Admission to the ICU of Onco-hematological Patients. NCT06113601	University Hospital A Coruña	—
Unknown	Testing Content Delivery Models for MomConnect NCT05505760	IDinsight	N/A
Active Not Recruiting	Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) NCT05329649	Vertex Pharmaceuticals Incorporated	Phase 3
Unknown	Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting NCT05041933	University Hospital, Limoges	—
Unknown	Carbapenem-resistant Organisms (CRO) Screening From Rectal Swabs in Patients With Hematological Diseases in Ch NCT05002582	Sir Run Run Shaw Hospital	—
Completed	XIENCE 28 USA Study NCT03815175	Abbott Medical Devices	N/A
Completed	A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease NCT03745287	Vertex Pharmaceuticals Incorporated	Phase 2 / Phase 3
Completed	Allo HSCT Using RIC for Hematological Diseases NCT02661035	Masonic Cancer Center, University of Minnesota	Phase 2
Unknown	MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engr NCT02240992	Nanfang Hospital, Southern Medical University	Phase 2 / Phase 3
Unknown	Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia NCT02241031	Nanfang Hospital, Southern Medical University	Phase 2 / Phase 3
Completed	Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (B NCT02483325	Institut Paoli-Calmettes	Phase 2
Unknown	Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function NCT02083718	Nanfang Hospital, Southern Medical University	Phase 2
Unknown	MSC for Treatment of CMV Infection NCT02083731	Nanfang Hospital, Southern Medical University	Phase 2
Completed	Daily Ginger Drinking and Platelet Function NCT02882776	King Abdullah International Medical Research Center	N/A
Unknown	Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure NCT01763099	Nanfang Hospital, Southern Medical University	Phase 2
Unknown	Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplan NCT01763086	Nanfang Hospital, Southern Medical University	Phase 2
Completed	Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients Wi NCT01344681	Yonsei University	Phase 2
Completed	Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? NCT00892502	Copenhagen University Hospital at Herlev	N/A
Unknown	Exercise During Chemotherapy for Patients With Hematological Malignancies NCT00884364	Charite University, Berlin, Germany	Phase 3
Unknown	Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itracon NCT01160952	Guangzhou General Hospital of Guangzhou Military Command	Phase 2
Completed	Study on Systemic and Airway Biomarkers in Haemopoietic Stem Cell Transplantation NCT00956358	The University of Hong Kong	—
Completed	Pilot Study of Non-Invasive Assessment of Hepatic And Myocardial Iron Through T2* Magnet Resonance Imaging (MR NCT00675038	St. Jude Children's Research Hospital	—
Unknown	Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) NCT00838643	Ospedale Santa Croce-Carle Cuneo	—
Completed	Capillary and Venous Blood Count Parameters NCT00390988	University of Magdeburg	—